Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
717 (USA) · Dr. Reyes
consented 2013-05-01
Adverse events
Moderate APPLICATION SITE PERSPIRATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-06-11 (study day 42.0); relationship: PROBABLE
Moderate APPLICATION SITE PERSPIRATION — outcome: RECOVERED/RESOLVED; onset 2013-06-11 (study day 42.0); relationship: PROBABLE
Moderate DIZZINESS — outcome: NOT RECOVERED/NOT RESOLVED; onset 1994-04; relationship: NONE
Moderate DIZZINESS — outcome: RECOVERED/RESOLVED; onset 2013-08-10 (study day 102.0); relationship: REMOTE
Mild NAUSEA — outcome: RECOVERED/RESOLVED; onset 2013-07-22 (study day 83.0); relationship: REMOTE
Moderate OEDEMA PERIPHERAL — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-29 (study day 29.0); relationship: POSSIBLE
Mild SKIN IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-23 (study day 23.0); relationship: PROBABLE
Moderate SKIN IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-23 (study day 23.0); relationship: PROBABLE
Moderate VOMITING — outcome: RECOVERED/RESOLVED; onset 2013-07-07 (study day 68.0); relationship: REMOTE
Data queries
No data queries.